Novo Nordisk A/S
CSE:NOVO B
Novo Nordisk A/S
CSE:NOVO B
Price:
257.9
DKK
-0.96%
Market Cap:
kr1.1T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Novo Nordisk A/S
CSE:NOVO B
|
DK |
|
We Win Ltd
NSE:WEWIN
|
IN |
Multiples-Based Value
The
Multiples-Based Value for
Novo Nordisk A/S (NOVO B)
under the Base Case is
622.43
DKK.
Compared with the current market price of 257.9 DKK, the stock appears
Undervalued by 59%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NOVO B
Multiples-Based Value
622.43
DKK
Undervaluation 59%
Multiples Across Competitors
NOVO B Competitors Multiples
Novo Nordisk A/S Competitors
Novo Nordisk A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.7 | 11.2 | 8.3 | 9.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 13.3 | 42.1 | 28.5 | 30.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 5.8 | 26.4 | 16.9 | 21.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 19.8 | 11.7 | 13.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 4.5 | 15.9 | 9.9 | 12 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 5 | 20.3 | 12.6 | 16.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 2.5 | 16.9 | 7.1 | 8.8 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
87.4B GBP | 2.7 | 15.3 | 8.3 | 10.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
